MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding MiNK Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 19 | 18 | −1 |
| Shares | 61.9K | 91.3K | +29.4K (+47.5%) |
| Value | $460.8K | $1.28M | +$817.8K (+177.5%) |
New holders (2)
Institutions that held MiNK Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 14,600 | $204.4K | 0.00% |
| Tower Research Capital LLC (TRC) | 926 | $13.0K | 0.00% |
Sold out (3)
Institutions that held MiNK Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Wells Fargo & Company | 849 | $6.27K |
| Total Investment Management Inc | 500 | $3.69K |
| Raymond James Financial Inc | 32 | $236 |